Gelonghui on September 23rd, Deqi Pharmaceuticals-B (06996.HK) announced that the Thai Food and Drug Administration has approved the new drug application (NDA) for Xiwio (Selinexor Tablets) for two indications: (1) in combination with bortezomib and dexamethasone, for the treatment of adult patients with multiple myeloma (MM) who have received at least one prior therapy; and (2) in combination with dexamethasone, for the treatment of adult patients with MM who have received at least four prior therapies, including at least two proteasome inhibitors, two immune modulators, and one anti-CD38 monoclonal antibody, and whose disease has progressed during or after their most recent treatment.
德琪医药-B(06996.HK)：希维奥两种适应症的新药上市申请获泰国食品药品监督管理局批准
Deqi Pharmaceutical-B (06996.HK): Applications for new drugs for two indications of Xiwio have been approved by the Thailand Food and Drug Administration.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated